These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 20238137)
1. Modeling stroke management: a qualitative review of cost-effectiveness analyses. Guilhaume C; Saragoussi D; Cochran J; François C; Toumi M Eur J Health Econ; 2010 Aug; 11(4):419-26. PubMed ID: 20238137 [TBL] [Abstract][Full Text] [Related]
2. Model-based cost-effectiveness analyses for the treatment of acute stroke events: a review and summary of challenges. Earnshaw SR; Wilson M; Mauskopf J; Joshi AV Value Health; 2009 Jun; 12(4):507-20. PubMed ID: 19900253 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia. Ademi Z; Pasupathi K; Liew D Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250 [TBL] [Abstract][Full Text] [Related]
4. Development of a decision-analytic model of stroke care in the United States and Europe. Chambers MG; Koch P; Hutton J Value Health; 2002; 5(2):82-97. PubMed ID: 11918824 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective. Chevalier J; Delaitre O; Hammès F; de Pouvourville G Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113 [TBL] [Abstract][Full Text] [Related]
6. Systematic assessment of decision-analytic models for chronic myeloid leukemia. Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259 [TBL] [Abstract][Full Text] [Related]
7. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US. von Schéele B; Fernandez M; Hogue SL; Kwong WJ Ann Pharmacother; 2013 May; 47(5):671-85. PubMed ID: 23606551 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Freeman JV; Zhu RP; Owens DK; Garber AM; Hutton DW; Go AS; Wang PJ; Turakhia MP Ann Intern Med; 2011 Jan; 154(1):1-11. PubMed ID: 21041570 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Kamel H; Johnston SC; Easton JD; Kim AS Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255 [TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Endovascular Stroke Therapy: A Patient Subgroup Analysis From a US Healthcare Perspective. Kunz WG; Hunink MG; Sommer WH; Beyer SE; Meinel FG; Dorn F; Wirth S; Reiser MF; Ertl-Wagner B; Thierfelder KM Stroke; 2016 Nov; 47(11):2797-2804. PubMed ID: 27758942 [TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. Nguyen E; Egri F; Mearns ES; White CM; Coleman CI Pharmacotherapy; 2016 May; 36(5):488-95. PubMed ID: 27015873 [TBL] [Abstract][Full Text] [Related]
12. Cost utility of hub-and-spoke telestroke networks from societal perspective. Demaerschalk BM; Switzer JA; Xie J; Fan L; Villa KF; Wu EQ Am J Manag Care; 2013 Dec; 19(12):976-85. PubMed ID: 24512034 [TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. Ehteshami-Afshar S; Zafari Z; Hamidi N; FitzGerald JM; Lynd L; Sadatsafavi M Value Health; 2019 Sep; 22(9):1070-1082. PubMed ID: 31511184 [TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke. Leppert MH; Campbell JD; Simpson JR; Burke JF Stroke; 2015 Jul; 46(7):1870-6. PubMed ID: 26012639 [TBL] [Abstract][Full Text] [Related]